The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Strategies for treating Richter’s transformation in CLL: checkpoint inhibitors and venetoclax
Richter’s transformation remains a challenge in chronic lymphocytic leukemia (CLL). In this interview, Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the key approaches being developed to address this issue, include immunotherapy and chemosensitivity enhancement. Dr Davids discusses promising recent and ongoing studies in these areas, including those investigating immune checkpoint inhibitors and venetoclax. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
